UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 17, 2016

 

 

CELGENE CORPORATION

(Exact name of registrant as specified in its charter)

 

 

Delaware	001-34912	22-2711928
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

 

86 Morris Avenue, Summit, New Jersey		07901
(Address of principal executive offices)		(Zip Code)

 

Registrant’s telephone number, including area code: (908) 673-9000

  

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

ITEM 8.01  OTHER EVENTS

 

On October 17, 2016, Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, issued a press release providing additional data on the ongoing phase 1b CD-001 study exploring the effects of oral GED-0301 (mongersen) on both endoscopic and clinical outcomes in patients with active Crohn’s disease. Attached hereto and incorporated herein by reference as Exhibit 99.1 is the press release announcement.

 

ITEM 9.01  FINANCIAL STATEMENTS AND EXHIBITS.

 

Exhibit 99.1 – Press Release dated October 17, 2016

 

SIGNATURES

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	CELGENE CORPORATION
Date:  October 17, 2016	By:	/s/ Peter N. Kellogg
		Peter N. Kellogg
		Executive Vice President and
		Chief Financial Officer
		(principal financial and accounting officer)

 

 

EXHIBIT INDEX

 

Exhibit No.		Description
99.1		Press Release dated October 17, 2016